TW318142B - - Google Patents

Download PDF

Info

Publication number
TW318142B
TW318142B TW081104221A TW81104221A TW318142B TW 318142 B TW318142 B TW 318142B TW 081104221 A TW081104221 A TW 081104221A TW 81104221 A TW81104221 A TW 81104221A TW 318142 B TW318142 B TW 318142B
Authority
TW
Taiwan
Prior art keywords
hhgf
heparin
acid
liver
growth factor
Prior art date
Application number
TW081104221A
Other languages
English (en)
Chinese (zh)
Original Assignee
Mitsubishi Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemicals Co Ltd filed Critical Mitsubishi Chemicals Co Ltd
Application granted granted Critical
Publication of TW318142B publication Critical patent/TW318142B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Materials For Medical Uses (AREA)
TW081104221A 1991-06-03 1992-05-29 TW318142B (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13127191 1991-06-03
JP3812292 1992-02-25

Publications (1)

Publication Number Publication Date
TW318142B true TW318142B (enExample) 1997-10-21

Family

ID=26377318

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081104221A TW318142B (enExample) 1991-06-03 1992-05-29

Country Status (9)

Country Link
US (2) US5545722A (enExample)
EP (1) EP0517182B1 (enExample)
KR (1) KR100210698B1 (enExample)
AT (1) ATE143810T1 (enExample)
CA (1) CA2070263A1 (enExample)
DE (1) DE69214355T2 (enExample)
ES (1) ES2094848T3 (enExample)
HU (1) HUT62315A (enExample)
TW (1) TW318142B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
TW318142B (enExample) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
GB9306255D0 (en) * 1993-03-25 1993-05-19 Cancer Res Campaign Tech Heparan sulphate oligosaccharides having hepatocyte growth factor binding affinity
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
EP0730466A4 (en) * 1993-09-10 1999-04-14 Univ New York COMPOSITIONS AND METHOD FOR INHIBITING THE INVASION OF HEPATOCYTES BY MALARIASPOROZOITES
US6756358B2 (en) 1994-08-19 2004-06-29 Sumitomo Pharmaceuticals Co., Ltd. Therapeutic agent for cartilaginous diseases
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
AU7389496A (en) * 1995-10-05 1997-04-28 Genentech Inc. Methods and compositions for treating vascular stenosis
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
WO2000024416A1 (en) * 1998-10-28 2000-05-04 Snow Brand Milk Products Co., Ltd. Remedies for bone metabolic errors
US7829072B2 (en) * 2000-07-14 2010-11-09 Carter Daniel C Serum albumin compositions for use in cleansing or dermatological products for skin or hair
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
SE525461C3 (sv) 2002-11-28 2005-03-23 Prophymed Ab Ny användning av dextransulfat
EP1575998A4 (en) * 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
TWI328614B (en) * 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
WO2005055949A2 (en) * 2003-12-09 2005-06-23 The Children's Hospital Of Philadelphia Sustained release preparations composed of biocompatible complex microparticles
SE538503C2 (en) 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045534A (ja) * 1983-08-22 1985-03-12 Otsuka Pharmaceut Co Ltd 肝実質細胞増殖因子
EP0412577A1 (de) * 1986-05-09 1991-02-13 Hoechst Aktiengesellschaft Herbizide Mittel
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
JPH0240399A (ja) * 1988-07-27 1990-02-09 Takeda Chem Ind Ltd 線維芽細胞増殖因子ムテインの複合体あるいは組成物
JPH0247916A (ja) * 1988-08-08 1990-02-16 Nec Corp アナログコンパレータ
US5013714A (en) * 1988-12-15 1991-05-07 Lindstrom Richard L Viscoelastic solution
US5486599A (en) * 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
CA2022752C (en) * 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
TW318142B (enExample) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd

Also Published As

Publication number Publication date
CA2070263A1 (en) 1992-12-04
US5736506A (en) 1998-04-07
ES2094848T3 (es) 1997-02-01
HU9201856D0 (en) 1992-08-28
KR100210698B1 (ko) 1999-07-15
HUT62315A (en) 1993-04-28
EP0517182B1 (en) 1996-10-09
DE69214355D1 (de) 1996-11-14
ATE143810T1 (de) 1996-10-15
KR930000120A (ko) 1993-01-15
DE69214355T2 (de) 1997-03-06
US5545722A (en) 1996-08-13
EP0517182A1 (en) 1992-12-09

Similar Documents

Publication Publication Date Title
TW464655B (en) Recombinant obese (OB) proteins
Zhang et al. Hydrogen peroxide preconditioning enhances the therapeutic efficacy of Wharton's Jelly mesenchymal stem cells after myocardial infarction
Chothia et al. Helix movements and the reconstruction of the haem pocket during the evolution of the cytochrome c family
AU704910B2 (en) Recombinant adenoviruses encoding glial cell neurotrophic factor (GDNF)
JP4617058B2 (ja) コンセンサスインターフェロンのＢ型肝炎表面抗原とｅ抗原の抑制剤としての応用
JPH07501206A (ja) 前駆肝細胞の増殖
CN116333094A (zh) 一种重组人源化I型胶原蛋白α1及表达载体和应用
Liu et al. Human umbilical vein endothelial cells-derived exosomes enhance cardiac function after acute myocardial infarction by activating the PI3K/AKT signaling pathway
EP0517182B1 (en) Hepatocyte-growth agent
WO2016197592A1 (zh) 一种长链非编码rna hnf1a-as1在制备治疗人体恶性实体瘤药物中的应用
WO2021068884A1 (zh) 多肽衍生物、纳米纤维及其应用
Zipori Cell interactions in the bone marrow microenvironment: role of endogenous colony‐stimulating activity
Makower et al. Effects of IGF-I, EGF, and FGF on proteoglycans synthesized by fractionated chondrocytes of rat rib growth plate
JP2010508845A5 (enExample)
Tan et al. Response of the sensorimotor cortex of cerebral palsy rats receiving transplantation of vascular endothelial growth factor 165-transfected neural stem cells
CN114702551B (zh) 促进肝细胞增殖和/或抑制肝细胞凋亡的多肽及其用途
CN106497875A (zh) 千金藤碱的应用以及一种扩增胎盘造血干细胞的培养基和方法
JPS61111693A (ja) λＰ▲Ｌの下つき▼プロモ−タ−とリボソ−ム結合部位の置換に便利なように工学処理した制限部位とを含有する発現ベクタ−、このベクタ−を含有するプラスミド、このプラスミドを含有する宿主、および関連方法
Nakamura et al. Two types of growth inhibitor in rat platelets for primary cultured rat hepatocytes
CN114796525A (zh) 细胞周期调控蛋白抑制剂在肿瘤治疗中的应用
KR20240124200A (ko) 염증성 장 질환 치료용 지질 나노입자
CN118290531A (zh) 一种碘-131标记的小分子多肽tfmp-y2及其制备方法和应用
Masuda et al. Airway epithelial cells enhance eosinophil survival
CN100537765C (zh) 重组人血管抑素k1-3的制备工艺及其制品在肿瘤治疗药物中的应用
CN103865899B (zh) 具有vegfr2/kdr受体特异性的融合毒素及其编码基因与应用